Pfizer's Xtandi delays prostate cancer spread in early stage disease

(Reuters) - Use of Xtandi in early stage prostate cancer on top of standard hormone therapy reduced the risk of disease spreading or death by 71 percent compared with hormone therapy alone, study results that could lead to significantly increased sales of the Pfizer Inc and Astellas Pharma Inc medicine.
Source: Reuters: Health - Category: Consumer Health News Tags: healthNews Source Type: news